---
title: "Trulicity (dulaglutide), all indications: Pharmacology questions"
description: "Pharmacology questions on Trulicity (dulaglutide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Components, and Pharmacokinetics. Questions: How does Trulicity work (mechanism of action)? What is the structure of the Trulicity (dulaglutide) molecule? What is the half-life of Trulicity? When does Trulicity reach peak and steady-state levels? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/trulicity/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Trulicity (dulaglutide), all indications: Pharmacology questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Trulicity](https://uspl.lilly.com/trulicity/trulicity.html#pi)  
Indication pages: [Type 2 diabetes](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes)

## Mechanism

<a id="trulicity-mechanism"></a>

### How does Trulicity work (mechanism of action)?

> “TRULICITY contains dulaglutide, which is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37). Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=TRULICITY%20contains%20dulaglutide%2C%20which%20is,secretion%20and%20slows%20gastric%20emptying.)

> “TRULICITY lowers fasting glucose and reduces postprandial glucose (PPG) concentrations in patients with type 2 diabetes mellitus. The reduction in fasting and postprandial glucose can be observed after a single dose.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=TRULICITY%20lowers%20fasting%20glucose%20and,observed%20after%20a%20single%20dose.)

## Components

<a id="trulicity-molecule-structure"></a>

### What is the structure of the Trulicity (dulaglutide) molecule?

> “The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell (Chinese hamster ovary) culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37). Structural modifications were introduced in the GLP-1 part of the molecule responsible for interaction with the enzyme dipeptidyl-peptidase-IV (DPP-4). Additional modifications were made in an area with a potential T-cell epitope and in the areas of the IgG4 Fc part of the molecule responsible for binding the high-affinity Fc receptors and half-antibody formation. The overall molecular weight of dulaglutide is approximately 63 kilodaltons.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20molecule%20is%20a%20fusion,dulaglutide%20is%20approximately%2063%20kilodaltons.)

> “Prolong incretin activity to enable once-weekly administration
> Amino acid substitution on human GLP-1 protects against DPP 4 degradation<sup>3-6</sup>
> Increasing the size of the molecule decreases renal clearance and extends the time-action profile<sup>4</sup>
> Eliminate the need for reconstitution
> Another amino acid substitution on human GLP-1 and fusion to the modified Fc portion of IgG4 improves solubility<sup>3-6</sup>”

Source: [TRULICITY: Resources for HCPs – Videos & FAQs, captured 2026-11-13](https://trulicity.lilly.com/hcp/resources#faq:~:text=Prolong%20incretin%20activity%20to%20enable,Fc%20portion%20of%20IgG4%20improves)

Note: The second passage is the answer to "How was the Trulicity molecule designed?" on the resources page of the Trulicity HCP site.

<a id="trulicity-inactive-ingredients"></a>

### What are the inactive ingredients in Trulicity?

> “TRULICITY (dulaglutide) injection is a clear, colorless, sterile, preservative-free solution for subcutaneous use. Each single-dose pen contains a 0.5 mL solution of 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg of dulaglutide and the following excipients: citric acid anhydrous (0.07 mg), mannitol (23.2 mg), polysorbate 80 (0.10 mg for 0.75 mg and 1.5 mg; 0.125 mg for 3 mg and 4.5 mg), and trisodium citrate dihydrate (1.37 mg), in water for injection.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=TRULICITY%20%28dulaglutide%29%20injection%20is%20a,mg%29%2C%20in%20water%20for%20injection.)

> “Inactive ingredients: citric acid anhydrous, mannitol, polysorbate 80, trisodium citrate dihydrate, in water for injection”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Inactive%20ingredients%3A%20citric%20acid%20anhydrous%2C,dihydrate%2C%20in%20water%20for%20injection)

## Pharmacokinetics

<a id="trulicity-half-life"></a>

### What is the half-life of Trulicity?

> “The apparent population mean clearance of dulaglutide was 0.142 L/h. The elimination half-life of dulaglutide was approximately 5 days.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20apparent%20population%20mean%20clearance,dulaglutide%20was%20approximately%205%20days.)

> “Once-weekly Trulicity has a plasma half-life of approximately 5 days.<sup>1</sup>”

Source: [TRULICITY: Resources for HCPs – Videos & FAQs, captured 2026-11-13](https://trulicity.lilly.com/hcp/resources#faq:~:text=Once%2Dweekly%20Trulicity%20has%20a%20plasma%20half%2Dlife%20of%20approximately%205)

<a id="trulicity-peak-steady-state"></a>

### When does Trulicity reach peak and steady-state levels?

> “Following subcutaneous administration, the time to maximum plasma concentration of dulaglutide at steady state ranges from 24 to 72 hours, with a median of 48 hours. After reaching steady state, the accumulation ratio was approximately 1.56. Steady-state plasma dulaglutide concentrations were achieved between 2 and 4 weeks following once weekly administration.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Following%20subcutaneous%20administration%2C%20the%20time,weeks%20following%20once%20weekly%20administration.)

> “Absorption – The mean absolute bioavailability of dulaglutide following subcutaneous administration of single 0.75 mg and 1.5 mg doses was 65% and 47%, respectively. Absolute subcutaneous bioavailability for 3 mg and 4.5 mg doses were estimated to be similar to 1.5 mg although this has not been specifically studied. Dulaglutide concentrations increased approximately proportional to dose from 0.75 mg to 4.5 mg.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Absorption%20%E2%80%93%20The%20mean%20absolute,0.75%20mg%20to%204.5%20mg.)

<a id="trulicity-metabolism"></a>

### How is Trulicity metabolized?

> “Metabolism – Dulaglutide is presumed to be degraded into its component amino acids by general protein catabolism pathways.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Metabolism%20%E2%80%93%20Dulaglutide%20is%20presumed,by%20general%20protein%20catabolism%20pathways.)

## Related pages
- [Medical information: Trulicity (dulaglutide): All indications](https://www.evicenter.com/medical-information/trulicity)
- [Indication](https://www.evicenter.com/medical-information/trulicity/indication)
- [Safety](https://www.evicenter.com/medical-information/trulicity/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trulicity/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/trulicity/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trulicity/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trulicity/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/trulicity/access-and-coverage)
